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MV-626, A Potent and Selective Inhibitor of ENPP1, Enhances STING Activation 
and Augments T-cell Mediated Anti-tumor Activity in Vivo 
Combination of MV-626 with Radiation Abstract 
 
MV-626 Enhances STING Responses 
Human Fibroblast 
activation 
•  Cells incubated with 
increasing concentrations 
of MV-626, with or without 
cGAMP (12.5 µM) for 
partial STING pathway 
activation 
•  IFNβ mRNA measured 
after cGAMP addition (RT-
PCR) 
MV-626 Inhibits ENPP1-Mediated 
Degradation of cGAMP 
Radiation Dose-Dependent Response 
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Concentration of MV-626 
Control VACV-70 3.0 µM MV-626 + VACV-70 
Human PBMC 
activation 
•  VAC-70 DNA (5 µg/mL) 
added to activate cGAS, 
which produces cGAMP 
•  MV-626 added to enhance 
STING pathway signaling 
•  IP-10 measured by 
ELISA at 19 hrs 
STING is an endogenous sensor of cGAMP, which is synthesized by 
cGAS following detection of cytoplasmic DNA. STING activation 
leads to interferon production and activation of inflammatory 
pathways that facilitate cytolytic T cell priming. STING agonists 
administered intratumorally show potent anti-tumor efficacy in a 
range of preclinical models; several agonists are in clinical 
development. Radiation therapy also increases cytoplasmic DNA 
levels in cancer cells, resulting in STING activation and secretion of 
inflammatory cytokines. Ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1) is the phosphodiesterase that 
negatively regulates STING by hydrolyzing cGAMP. MV-626, a highly 
potent and selective ENPP1 inhibitor with 100% oral bioavailability in 
rats and mice, blocks cGAMP hydrolysis and increases STING 
activation in cells where cGAS is active. We hypothesize that by 
conditionally enhancing STING activation, ENPP1 inhibitors will 
facilitate development of anti-tumor cellular immune responses, 
particularly following radiation therapy.
The effects of ENPP1 inhibition on STING activation using cGAMP 
or DNA treatment of cells were assessed in vitro. Panc02-SIY 
tumors were implanted in C57BL/6 mice and randomized to receive 
20Gy CT-guided radiation therapy, 5 daily ip doses of MV-626, or 
both MV-626 and radiation. Mice were followed for outcome, tumor 
antigen specific T cell responses and changes in the tumor immune 
environment. Additional studies were conducted in C57BL/6 mice 
bearing MC38 tumors treated with anti-PDL1, MV-626 or MV-626 + 
anti-PDL1. 
In vitro, MV-626 blocks ENPP1-mediated hydrolysis of cGAMP and 
enhances STING activation by DNA-mediated cGAS activation or 
exogenous cGAMP. Therapeutic doses of MV-626 were well 
tolerated in mice, with no evidence of toxicity or clinically-
significant increases in systemic cytokine levels. Systemic 
administration of MV-626 monotherapy caused tumor growth delay. 
MV-626 combined with radiation therapy significantly increased 
overall survival, and most animals achieved durable tumor cures. 
Additional studies in the MC38 model confirmed MV-626 activity. 
Studies characterizing effects of MV-626 in the tumor 
microenvironment are underway.
Results
Methods
Background
STING Pathway is a Central Mediator of 
Anti-Tumor Immune Response 
Immunogenic Death
(spontaneous 
or induced)
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MV-626 Shows Monotherapy Activity and Enhances 
anti-PD-L1 Efficacy in MC38 Tumor Model
Conclusions 
 These data demonstrate the potent and selective ENPP1 inhibitor 
MV-626, when delivered orally or IP, augments STING activation 
in vitro and enhances immune responses to tumors in vivo. We 
demonstrate for the first time that, in combination with radiation 
therapy or anti-PDL1 mAb treatment, ENPP1 inhibition improves 
outcomes and cures tumors in preclinical models through 
changes in the tumor immune environment. The loss of this 
efficacy in IFN receptor knockout mice confirms STING-pathway 
mechanism of action, and the ability of the majority of MV-626 
treated mice to reject tumor rechallenge indicates that MV-626 
drives disseminated, durable, adaptive immune response. These 
translational studies demonstrate a novel approach to STING 
pathway modulation and form the foundation for clinical 
development of an ENPP1 inhibitor as a cancer immunotherapy. 
Future Directions 
•  Role of host STING activation and CD8 T cells 
•  Additional profiling of tumor antigen specific 
responses 
•  Evaluate distal tumor responses 
•  Clinical translation – biomarker identification
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Syngeneic Panc02  
Tumor Model 
Single flank 
inoculation 
MV-626 (60 mg/kg QD IP x5) 
Tumors grown 
for 7 days 
RT 20 Gy x 1 
MV-626 + RT 20 Gy x 1 
Da
y 
8 
Da
y 
9 
Immunocompetent 
mice 
Vehicle (QD IP x5) 
Follow for efficacy 
Rechallenge cures 
- 6/6 mice treated w/
MV-626 + RT were 
cured by day 28
- All 6 cured mice 
were rechallenged at 
day 80
- 4/6 mice rejected the 
rechallenge, indicating 
durable anti-tumor 
immunity
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WT and Interferon Receptor (IFNAR) KO Mice 
WT, MV-626 + RT IFNAR KO, MV-626 + RT 
- Loss of MV-626 
efficacy in IFNAR KO 
mice indicates a type 
1 IFN-dependent 
MOA
-  MAVU-626 was dosed at 50 mg/kg PO QD on days 15 -36; data presented as mean +/- SEM    
-  Anti-PD-L1 mAb (10 mg/kg) was dosed twice weekly x 6 doses beginning on day 14
-  Only anti-PD-L1 + 50 mg/kg MAVU-626 group had survival with p<0.05 vs vehicle  
    (Wilcoxon; no animals were censored) 
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MV-626
20Gy 
21Gy 
22Gy 
19Gy 
18Gy 
17Gy 
CT isocenter Segmentation Treatment dose 
PARAMETER MV-626 
ENPP1 Ki (human)	US034-0004515-Q01	and	
US034-004516-Q01 ~5 nM 
ENPP1 Ki (mouse) ~18 nM 
Solubility 11 µM 
Mouse PK: Clearance 1.68 ml/min/kg 
Mouse PK: terminal half life 8.8 hours 
Rat PK: Clearance (mL/min/kg) 1.8 ml/min/kg 
Rat PK: terminal half life 6.7 hours 
Oral bioavailability 100% rat , 100% mouse 
Selectivity vs canonical PDEs (1-12) >500 
•  Nanostring profiling of immune changes in the 
tumor and LN 
•  Evaluation of ENPP1 inhibition with other anti-
cancer agents that  produce immunogenic 
tumor cell death 
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